FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Can J Vet Res / Equine pituitary pars intermedia dysfunction: An internation...
Canadian journal of veterinary research = Revue canadienne de recherche veterinaire2017; 81(4); 261-269;

Equine pituitary pars intermedia dysfunction: An international survey of veterinarians’ approach to diagnosis, management, and estimated prevalence.

Abstract: The objectives of the present study were to determine if diagnosis and treatment of equine pituitary pars intermedia dysfunction (PPID) vary by geographic region and to report the prevalence of PPID in horses as observed by veterinarians across locations. An online questionnaire was developed for veterinarians who treat horses. Veterinary associations, especially equine specialty subgroups, were contacted and a survey link was sent to members of each organization. Generalized linear models were used to examine whether the method of diagnosis and treatment of this condition, as well as its reported prevalence, differed by geographic region. Veterinarians from 426 separate clinics in 20 countries returned surveys. Diagnosis of PPID varied by region, but was usually based on clinical signs and an adjunct endocrine test. Horses with PPID were treated medically by 63% of veterinarians and 75% of these used pergolide mesylate as treatment. The median prevalence estimated was 1% and this did not differ by geographic location. Half the veterinarians were caring for 5 or more animals with PPID. Overall, diagnostic approach differed in geographic regions. In general, European veterinarians were more likely than those in North America to diagnose PPID based on clinical signs alone, without using an adjunct laboratory test. Veterinarians reported that cost and management responsibilities were their clients' primary concerns associated with the long-term treatment of this disease, which indicates a need for additional treatment options for PPID. Les objectifs de la présente étude étaient de déterminer si le diagnostic et le traitement de la dysfonction de l’hypophyse médiale équine (DHME) varient selon la région géographique et signalent la prévalence de la DHME chez les chevaux, comme l’ont observé les vétérinaires dans différentes localisations. Un questionnaire en ligne a été développé pour les vétérinaires qui traitent les chevaux. Les associations vétérinaires, en particulier les sous-groupes de spécialités équines, ont été contactées et un lien pour un sondage a été envoyé aux membres de chaque organisation. Les modèles linéaires généralisés ont été utilisés pour examiner si la méthode de diagnostic et de traitement de cette condition, ainsi que sa prévalence déclarée, différaient selon la région géographique. Les vétérinaires provenant de 426 cliniques distinctes dans 20 pays ont répondu au sondage. Le diagnostic de DHME variait selon la région, mais était généralement basé sur les signes cliniques et un test endocrinien complémentaire. Les chevaux atteints de DHME ont été traités médicalement par 63 % des vétérinaires et 75 % de ceux-ci utilisaient le mésylate de pergolide comme traitement. La prévalence médiane estimée était de 1 % et cela ne différait pas selon la situation géographique. La moitié des vétérinaires prenaient soin de 5 animaux ou plus avec DHME. Dans l’ensemble, l’approche diagnostique différait selon les régions géographiques. En général, les vétérinaires européens étaient plus susceptibles que ceux en Amérique du Nord de diagnostiquer la DHME en se basant uniquement sur les signes cliniques, sans utiliser un test de laboratoire complémentaire. Les vétérinaires ont signalé que les coûts et les responsabilités en matière de gestion étaient les principales préoccupations de leurs clients liées au traitement à long terme de cette maladie, ce qui indique un besoin d’options de traitement supplémentaires pour DHME.(Traduit par Docteur Serge Messier).
Get Full Text
Publication Date: 2017-10-31 PubMed ID: 29081583PubMed Central: PMC5644449
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article focuses on a study aiming to understand how the diagnosis and treatment of equine pituitary pars intermedia dysfunction (PPID) differ by geographic location. The study also reports on the prevalence of PPID in horses as observed by veterinarians across different regions.

Research Methodology

  • The research involved conducting an online questionnaire for veterinarians who treat horses. The questionnaire was widely circulated among veterinary associations, with a special focus on equine specialty subgroups.
  • Responses to the survey were collected from 426 separate clinics situated in 20 different countries, making the study truly international.
  • Generalized linear models were utilized to examine if the method of diagnosis and treatment of PPID, as well as its reported prevalence, varied by different geographical regions.

Research Findings

  • Results showed that the diagnosis of PPID varied by region. Typically, diagnosis was based on clinical signs along with an auxiliary endocrine test.
  • Among respondents, about 63% of veterinarians reported treating horses with PPID medically, and of these, 75% used pergolide mesylate as the treatment. This reveals pergolide mesylate to be the preferred treatment for PPID among vets.
  • Estimates for the median prevalence of PPID were found to be about 1%, with no significant differences observed based on geographical location.
  • Half the responding veterinarians reported treating five or more animals suffering from PPID.

Geographic Differences and Other Observations

  • Findings indicated differences in approaches to diagnosing PPID based on geographic regions. European veterinarians were found to rely more on clinical signs alone without utilizing adjunct laboratory tests, contrasted with their counterparts in North America.
  • Veterinarians reported cost and management responsibilities as the primary concerns of their clients when it came to the long-term treatment of PPID. This observation flagged the need for exploring additional treatment options for PPID.

In conclusion, this international survey offers insights into how veterinarians approach the diagnosis and treatment of PPID across different geographical locations. The study also highlights significant concerns related to cost and management responsibilities tied to the condition’s long-term treatment, pointing to a need for more varied treatment options.

Cite This Article

APA
Carmalt JL, Waldner CL, Allen AL. (2017). Equine pituitary pars intermedia dysfunction: An international survey of veterinarians’ approach to diagnosis, management, and estimated prevalence. Can J Vet Res, 81(4), 261-269.

Publication

Canadian journal of veterinary research = Revue canadienne de recherche veterinaire
ISSN: 1928-9022
NlmUniqueID: 8607793
Country: Canada
Language: English
Volume: 81
Issue: 4
Pages: 261-269

Researcher Affiliations

Carmalt, James L
  • Department of Large Animal Clinical Sciences (Carmalt, Waldner) and Department of Veterinary Pathology (Allen), Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, Saskatchewan S7N 5B4.
Waldner, Cheryl L
  • Department of Large Animal Clinical Sciences (Carmalt, Waldner) and Department of Veterinary Pathology (Allen), Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, Saskatchewan S7N 5B4.
Allen, Andrew L
  • Department of Large Animal Clinical Sciences (Carmalt, Waldner) and Department of Veterinary Pathology (Allen), Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, Saskatchewan S7N 5B4.

MeSH Terms

  • Animals
  • Canada / epidemiology
  • Data Collection
  • Horse Diseases / diagnosis
  • Horse Diseases / epidemiology
  • Horses
  • Pituitary ACTH Hypersecretion / diagnosis
  • Pituitary ACTH Hypersecretion / epidemiology
  • Pituitary ACTH Hypersecretion / veterinary
  • Pituitary Gland, Intermediate / pathology
  • Risk Factors
  • Surveys and Questionnaires
  • Veterinarians

References

This article includes 38 references
  1. Toribio RE. Diagnosing equine pars intermedia dysfunction: are we there yet?. J Vet Intern Med 2005 Mar-Apr;19(2):145-6.
    pubmed: 15822556
  2. Schott HC 2nd. Pituitary pars intermedia dysfunction: equine Cushing's disease.. Vet Clin North Am Equine Pract 2002 Aug;18(2):237-70.
    pubmed: 15635907doi: 10.1016/s0749-0739(02)00018-4google scholar: lookup
  3. Orth DN, Holscher MA, Wilson MG, Nicholson WE, Plue RE, Mount CD. Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests.. Endocrinology 1982 Apr;110(4):1430-41.
    pubmed: 6277607doi: 10.1210/endo-110-4-1430google scholar: lookup
  4. Johnson PJ, Messer NT, Ganjam VK. Pituitary pars intermedia dysfunction (equine Cushing’s syndrome). In: McKinnon AO, Squires L, Vaala WE, Varner DD, editors. Equine Reproduction. 2nd ed. Ames: Wiley-Blackwell; 2011. pp. 2790–2795.
  5. Evans DR. The recognition and diagnosis of a pituitary tumor in the horse. Proc Am Assoc Eq Pract 1972;18:417–419.
  6. van der Kolk JH, Kalsbeek HC, van Garderen E, Wensing T, Breukink HJ. Equine pituitary neoplasia: a clinical report of 21 cases (1990-1992).. Vet Rec 1993 Dec 11;133(24):594-7.
    pubmed: 8116170
  7. Mellor DJ, Love S, Walker R, Gettinby G, Reid SW. Sentinel practice-based survey of the management and health of horses in northern Britain.. Vet Rec 2001 Oct 6;149(14):417-23.
    pubmed: 11678214doi: 10.1136/vr.149.14.417google scholar: lookup
  8. Chandler KJ, Mellor DJ. A pilot study of the prevalence of disease within a geriatric horse population. Proc Congr Brit Equine Vet Assoc 2011:217.
  9. Brosnahan MM, Paradis MR. Demographic and clinical characteristics of geriatric horses: 467 cases (1989-1999).. J Am Vet Med Assoc 2003 Jul 1;223(1):93-8.
    pubmed: 12839071doi: 10.2460/javma.2003.223.93google scholar: lookup
  10. Brosnahan MM, Paradis MR. Assessment of clinical characteristics, management practices, and activities of geriatric horses.. J Am Vet Med Assoc 2003 Jul 1;223(1):99-103.
    pubmed: 12839072doi: 10.2460/javma.2003.223.99google scholar: lookup
  11. Ireland JL, Clegg PD, McGowan CM, McKane SA, Pinchbeck GL. A cross-sectional study of geriatric horses in the United Kingdom. Part 2: Health care and disease.. Equine Vet J 2011 Jan;43(1):37-44.
    pubmed: 21143632doi: 10.1111/j.2042-3306.2010.00142.xgoogle scholar: lookup
  12. Rohrbach BW, Stafford JR, Clermont RS, Reed SM, Schott HC 2nd, Andrews FM. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.. J Vet Intern Med 2012 Jul-Aug;26(4):1027-34.
    pubmed: 22524260doi: 10.1111/j.1939-1676.2012.00932.xgoogle scholar: lookup
  13. Ireland JL, Wylie CE, Collins SN, Verheyen KL, Newton JR. Preventive health care and owner-reported disease prevalence of horses and ponies in Great Britain.. Res Vet Sci 2013 Oct;95(2):418-24.
    pubmed: 23768693doi: 10.1016/j.rvsc.2013.05.007google scholar: lookup
  14. McGowan TW, Pinchbeck GP, McGowan CM. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.. Equine Vet J 2013 Jan;45(1):74-9.
    pubmed: 22594955doi: 10.1111/j.2042-3306.2012.00578.xgoogle scholar: lookup
  15. Welsh CE, Duz M, Parkin TDH, Marshall JF. Prevalence, survival analysis and multimorbidity of chronic diseases in the general veterinarian-attended horse population of the UK.. Prev Vet Med 2016 Sep 1;131:137-145.
    pubmed: 27544263doi: 10.1016/j.prevetmed.2016.07.011google scholar: lookup
  16. McFarlane D, Dybdal N, Donaldson MT, Miller L, Cribb AE. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.. J Neuroendocrinol 2005 Feb;17(2):73-80.
    pubmed: 15796757doi: 10.1111/j.1365-2826.2005.01277.xgoogle scholar: lookup
  17. Glover CM, Miller LM, Dybdal NO, Lopez A, Duckett WA, McFarlane D. Extrapituitary and pituitary pathological findings in horses with pituitary pars intermedia dysfunction: A retrospective study. J Equine Vet Sci 2009;29:146–153.
  18. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: a metaanalysis.. Environ Res 2001 Jun;86(2):122-7.
    pubmed: 11437458doi: 10.1006/enrs.2001.4264google scholar: lookup
  19. Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries.. Neuroepidemiology 2010;34(3):143-51.
    pmc: PMC2865395pubmed: 20090375doi: 10.1159/000275491google scholar: lookup
  20. Dohoo I, Martin W, Stryhn H. Veterinary Epidemiologic Research. 2nd ed. Charlottetown, Prince Edward Island: VER Inc; 2012. Model-building strategies; pp. 365–394.
  21. Frank N, Andrews FM, Sommardahl CS, Eiler H, Rohrbach BW, Donnell RL. Evaluation of the combined dexamethasone suppression/ thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses.. J Vet Intern Med 2006 Jul-Aug;20(4):987-93.
    pubmed: 16955827doi: 10.1892/0891-6640(2006)20[987:eotcdt]2.0.co;2google scholar: lookup
  22. Okada T, Shimomuro T, Oikawa M, Nambo Y, Kiso Y, Morikawa Y, Liptrap RM, Yamashiro S, Little PB, Sasaki F. Immunocytochemical localization of adrenocorticotropic hormone-immunoreactive cells of the pars intermedia in thoroughbreds.. Am J Vet Res 1997 Aug;58(8):920-4.
    pubmed: 9256982
  23. van der Kolk JH, Heinrichs M, van Amerongen JD, Stooker RC, in de Wal LJ, van den Ingh TS. Evaluation of pituitary gland anatomy and histopathologic findings in clinically normal horses and horses and ponies with pituitary pars intermedia adenoma.. Am J Vet Res 2004 Dec;65(12):1701-7.
    pubmed: 15631037doi: 10.2460/ajvr.2004.65.1701google scholar: lookup
  24. Dybdal NO, Hargreaves KM, Madigan JE, Gribble DH, Kennedy PC, Stabenfeldt GH. Diagnostic testing for pituitary pars intermedia dysfunction in horses.. J Am Vet Med Assoc 1994 Feb 15;204(4):627-32.
    pubmed: 8163420
  25. van der Kolk JH, Wensing T, Kalsbeek HC, Breukink HJ. Laboratory diagnosis of equine pituitary pars intermedia adenoma.. Domest Anim Endocrinol 1995 Jan;12(1):35-9.
    pubmed: 7621678doi: 10.1016/0739-7240(94)00006-mgoogle scholar: lookup
  26. Couëtil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism.. J Vet Intern Med 1996 Jan-Feb;10(1):1-6.
    pubmed: 8965262doi: 10.1111/j.1939-1676.1996.tb02016.xgoogle scholar: lookup
  27. Mc Gowan TW, Pinchbeck GP, Mc Gowan CM. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.. Equine Vet J 2013 Jan;45(1):66-73.
    pubmed: 22563728doi: 10.1111/j.2042-3306.2012.00575.xgoogle scholar: lookup
  28. Perkins GA, Lamb S, Erb HN, Schanbacher B, Nydam DV, Divers TJ. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.. Equine Vet J 2002 Nov;34(7):679-85.
    pubmed: 12455838doi: 10.2746/042516402776250333google scholar: lookup
  29. Donaldson MT, McDonnell SM, Schanbacher BJ, Lamb SV, McFarlane D, Beech J. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses.. J Vet Intern Med 2005 Mar-Apr;19(2):217-22.
    pubmed: 15822567doi: 10.1892/0891-6640(2005)19<217:vipahc>2.0.co;2google scholar: lookup
  30. Donaldson MT, Jorgensen AJ, Beech J. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.. J Am Vet Med Assoc 2004 Apr 1;224(7):1123-7.
    pubmed: 15074858doi: 10.2460/javma.2004.224.1123google scholar: lookup
  31. Stanley SD, DiMaio Knych H. Comparison of pharmaceutical equivalence for compounded preparations of pergolide mesylate. Proc Annu Conf Am Assoc Eq Pract 2010;65:274–276.
  32. Davis JL, Kirk LM, Davidson GS, Papich MG. Effects of compounding and storage conditions on stability of pergolide mesylate.. J Am Vet Med Assoc 2009 Feb 1;234(3):385-9.
    pubmed: 19210262doi: 10.2460/javma.234.3.385google scholar: lookup
  33. Muñoz MC, Doreste F, Ferrer O, González J, Montoya JA. Pergolide treatment for Cushing's syndrome in a horse.. Vet Rec 1996 Jul 13;139(2):41-3.
    pubmed: 8839490doi: 10.1136/vr.139.2.41google scholar: lookup
  34. Schott HC, Coursen CL, Eberhart SW. The Michigan Cushing’s project. Proc Annu Conf Am Assoc Eq Pract 2001;47:22–24.
  35. Donaldson MT, LaMonte BH, Morresey P, Smith G, Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).. J Vet Intern Med 2002 Nov-Dec;16(6):742-6.
    pubmed: 12465775doi: 10.1892/0891-6640(2002)016<0742:twpoco>2.3.co;2google scholar: lookup
  36. Sgorbini M, Panzani D, Maccheroni M, Corazza M. Equine cushing-like syndrome: diagnosis and therapy in two cases.. Vet Res Commun 2004 Aug;28 Suppl 1:377-80.
    pubmed: 15373001doi: 10.1023/b:verc.0000045368.38959.8bgoogle scholar: lookup
  37. Thompson RJ, Gustafson KE. Adaptation to Chronic Childhood Illness. Washington, DC: American Psychological Association; 1996.
  38. Kelly MA. Managing a pet’s chronic illness: Factors that influence psychosocial adjustment. PhD thesis. Champaign, Illinois: University of Illinois; 2014.

Citations

This article has been cited 4 times.
  1. Kirkwood NC, Hughes KJ, Stewart AJ. Prospective Case Series of Clinical Signs and Adrenocorticotrophin (ACTH) Concentrations in Seven Horses Transitioning to Pituitary Pars Intermedia Dysfunction (PPID).. Vet Sci 2022 Oct 17;9(10).
    doi: 10.3390/vetsci9100572pubmed: 36288186google scholar: lookup
  2. Kirkwood NC, Hughes KJ, Stewart AJ. Pituitary Pars Intermedia Dysfunction (PPID) in Horses.. Vet Sci 2022 Oct 10;9(10).
    doi: 10.3390/vetsci9100556pubmed: 36288169google scholar: lookup
  3. Haffner JC, Neal DL, Hoffman RM, Grubbs ST. Plasma adrenocorticotropic hormone concentration in horses decreases after freezing for 60 days.. J Vet Diagn Invest 2019 Nov;31(6):856-858.
    doi: 10.1177/1040638719882374pubmed: 31646941google scholar: lookup
  4. Shepard KN, Haffner JC, Neal DL, Grubbs ST, Pearce GL. Effect of delayed plasma centrifugation on equine adrenocorticotropic hormone concentration.. J Vet Diagn Invest 2019 Jul;31(4):585-587.
    doi: 10.1177/1040638719860877pubmed: 31246158google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.